[DNDi Press Release] Geneva, Switzerland – 2 April 2019 Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR The Global Antibiotic Research and Development Partnership (GARDP) is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun […] Continue reading ->
Expanding access to costly cancer treatments and the high price of new generation insulin formulas were among the controversial topics of debate today as the WHO Expert Committee on the Selection and Use of Essential Medicines convened for its biennial update of the list of over 400 drugs deemed most essential for treating public health needs […] Continue reading ->
A “broader” call to action engaging a “wider universe of advocates,” is needed to more effectively tackle antimicrobial resistance (AMR) – including everyone from financial investors to environmental groups. This was the message emerging out of a global meeting on the issue yesterday in London. Image Credits: The Economist. Continue reading ->
Bacteria and other pathogens that are resistant to common anti-microbial medications appear to be most abundant in Africa, as well as parts of South-East Asia and other developing regions with a poor record of sewage and sanitation management, according to a new study published in Nature Communications. Image Credits: Wikimedia Commons. Continue reading ->
The Coalition for Epidemic Preparedness Innovations (CEPI), an innovative collaboration of governments, UN agencies, foundations and the private sector, has reaffirmed its commitment to safeguard and promote equitable access to new vaccines under development to head off the risk of disease outbreaks, epidemics and pandemics that threaten global health. Image Credits: CEPI / CureVac. Continue reading ->